ArticleJournal of medical virology2026
Cytomegalovirus Reactivation During Therapy for Pediatric Acute Lymphoblastic Leukemia.
Article in Journal of medical virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cytomegalovirus Reactivation During Therapy for Pediatric Acute Lymphoblastic Leukemia.Journal of medical virology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytomegalovirus (CMV) reactivation is a recognized complication after hematopoietic stem cell transplantation, but its relevance during conventional chemotherapy for pediatric acute lymphoblastic leukemia (ALL) is poorly defined, especially in CMV-prevalent regions. This retrospective cross-sectional study was conducted at a tertiary pediatric oncology center in South India from January 2020 to August 2025. Children (≤ 18 years) with ALL who developed CMV reactivation during chemotherapy were included. CMV testing was performed based on clinical indications, and viral load was quantified using multiplex polymerase chain reaction. Demographic, clinical, laboratory, treatment, and outcome data were analyzed. Of 150 children treated for ALL, 29 (19.3%) experienced CMV reactivation. The median age was 6 years, with a male predominance (72.4%). Reactivation occurred predominantly during consolidation (51.7%) and maintenance (41.4%) phases. Fever was the most common presentation (75.9%). The median CMV viral load was 1.48 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.